Search hospitals > Virginia > Richmond
Virginia Commonwealth University
Claim this profileRichmond, Virginia 23219
Global Leader in Heart Failure
Global Leader in Fibrosis
Conducts research for Non-alcoholic Fatty Liver Disease
Conducts research for Fatty Liver Disease
Conducts research for High Blood Pressure
828 reported clinical trials
78 medical researchers
Summary
Virginia Commonwealth University is a medical facility located in Richmond, Virginia. This center is recognized for care of Heart Failure, Fibrosis, Non-alcoholic Fatty Liver Disease, Fatty Liver Disease, High Blood Pressure and other specialties. Virginia Commonwealth University is involved with conducting 828 clinical trials across 930 conditions. There are 78 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Keri Maher.Area of expertise
1Heart Failure
Global LeaderStage I
Stage IV
Stage II
2Fibrosis
Global LeaderStage IV
CFTR positive
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center7 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Leslie Randall, MDVCU Massey Cancer Center1 year of reported clinical research
Studies Ovarian Cancer
Studies Cancer
18 reported clinical trials
33 drugs studied
Keri MaherVirginia Commonwealth University/Massey Cancer Center1 year of reported clinical research
Expert in Leukemia
Studies Myeloid Leukemia
15 reported clinical trials
36 drugs studied
Clinical Trials running at Virginia Commonwealth University
Lymphoma
Myotonic Dystrophy
Pulmonary Fibrosis
Breast Cancer
Traumatic Brain Injury
Duchenne Muscular Dystrophy
Follicular Lymphoma
Cystic Fibrosis
Fibrosis
B-Cell Lymphoma
Epcoritamab + R2
for Follicular Lymphoma
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting3 awards Phase 3
Epcoritamab + R-CHOP
for Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Recruiting2 awards Phase 3
Axicabtagene Ciloleucel
for Lymphoma
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Commonwealth University?
Virginia Commonwealth University is a medical facility located in Richmond, Virginia. This center is recognized for care of Heart Failure, Fibrosis, Non-alcoholic Fatty Liver Disease, Fatty Liver Disease, High Blood Pressure and other specialties. Virginia Commonwealth University is involved with conducting 828 clinical trials across 930 conditions. There are 78 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Keri Maher.
Where is Virginia Commonwealth University located?
**Virginia Commonwealth University (VCU) Medical Center**
- **Location:** 1200 E. Marshall St., Richmond, VA 23298
- **Directions:** From I-95 S, take Exit 74B toward Downtown/Manchester. Continue to 10th St., take the exit, turn right onto E. Leigh St., then left onto N. 12th St. The hospital is on your right.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Virginia Commonwealth University (VCU) Hospital, contact the Financial Counseling Call Center at (804) 828-0966. For insurance-related inquiries, reach out to VCU Health customer service at (804). Assistance with billing and insurance matters is also available through the VCUHS Financial Counseling Phone Unit.
What insurance does Virginia Commonwealth University accept?
Virginia Commonwealth University (VCU) offers a student health insurance program through United Health Care for full-time Ph.D. students, first professional students, and international students on F- and J-visas. Employees have access to health benefits coverage options provided by the Commonwealth of Virginia, including COVA Care, COVA HealthAware, COVA High Deductible Health Plan (HDHP), and COVA HealthAware. VCU postdocs must have appropriate health insurance, with three plans available through Anthem Blue Cross and Blue Shield, all including dental coverage.
VCU Health participates in a variety of health plans, such as Medicare, Medicaid of Virginia, Tricare, Aetna, Anthem, CIGNA, MedCost/Virginia Health Network, Multiplan/PHCS, Sentara Health Plan, Oscar Exchange, and United Healthcare Insurances.
What awards or recognition has Virginia Commonwealth University received?
Virginia Commonwealth University (VCU) Hospital, located in Richmond, Virginia, is renowned for its exceptional patient care, with all VCU Health System hospitals receiving a 4-out-of-5 star rating from the Centers for Medicare and Medicaid Services. The Children's Hospital of Richmond at VCU is recognized among the top 50 hospitals in the U.S. for pediatric care by U.S. News & World Report's 2021-22 Best Children’s Hospitals rankings.